1. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors.
- Author
-
Atsuta, Y, Baldomero, H, Neumann, D, Sureda, A, DeVos, JD, Iida, M, Karduss, A, Purtill, D, Elhaddad, AM, Bazuaye, NG, Bonfim, C, De la Camara, R, Chaudhri, NA, Ciceri, F, Correa, C, Frutos, C, Galeano, S, Garderet, L, Gonzalez-Ramella, O, Greco, R, Hamad, N, Hazenberg, MD, Horowitz, MM, Kalwak, K, Ko, B-S, Kodera, Y, Koh, MB, Liu, K, McLornan, DP, Moon, JH, Neven, B, Okamoto, S, Pasquini, MC, Passweg, JR, Paulson, K, Rondelli, D, Ruggeri, A, Seber, A, Snowden, JA, Srivastava, A, Szer, J, Weisdorf, D, Worel, N, Greinix, H, Saber, W, Aljurf, M, Niederwieser, D, Atsuta, Y, Baldomero, H, Neumann, D, Sureda, A, DeVos, JD, Iida, M, Karduss, A, Purtill, D, Elhaddad, AM, Bazuaye, NG, Bonfim, C, De la Camara, R, Chaudhri, NA, Ciceri, F, Correa, C, Frutos, C, Galeano, S, Garderet, L, Gonzalez-Ramella, O, Greco, R, Hamad, N, Hazenberg, MD, Horowitz, MM, Kalwak, K, Ko, B-S, Kodera, Y, Koh, MB, Liu, K, McLornan, DP, Moon, JH, Neven, B, Okamoto, S, Pasquini, MC, Passweg, JR, Paulson, K, Rondelli, D, Ruggeri, A, Seber, A, Snowden, JA, Srivastava, A, Szer, J, Weisdorf, D, Worel, N, Greinix, H, Saber, W, Aljurf, M, and Niederwieser, D
- Abstract
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-Governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries and individual centers including indication, donor type (allogeneic/autologous), donor match and stem cell source (bone marrow/peripheral blood stem cells/cord blood). In 2018, 1,768 HCT teams in 89 countries (six WHO regions) reported 93,105 (48,680 autologous and 44,425 allogeneic) HCT. Major indications were plasma cell disorders and lymphoma for autologous, and acute leukemias and MDS/MPN for allogeneic HCT. HCT number increased from 48,709 in 2007. Notable increases were seen for autoimmune diseases in autologous and hemoglobinopathies in allogeneic HCT. The number of allogeneic HCT more than doubled with significant changes in donor match. While HCT from HLA identical siblings has seen only limited growth, HCT from non-identical related donors showed significant increase worldwide. Strongest correlation between economic growth indicator of gross national income/capita and HCT activity/ten million population was observed for autologous HCT (r=0.79). HCT from unrelated donors showed strong correlation (r=0.68), but only moderate correlation (r=0.51) was detected from related donors. The use of HCT doubled in about a decade worldwide at different speed and with significant changes regarding donor match as a sign of improved access to HCT worldwide. Although narrowing, significant gaps remain between developing and non-developing countries.
- Published
- 2024